MUC13

Across TCGA pan-cancer cohorts, MUC13 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MUC13 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MUC13 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MUC13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, BLCA, and LUSC are the cancer types where MUC13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.189	0.682	.004	24	view →
BLCA	OS	Median	III,IV	0.089	0.684	<.001	12	view →
LUSC	OS	Median	II,III,IV	0.002	0.743	<.001	12	view →
UCEC	DFS	Median	II,III,IV	0.922	0.305	.019	10	view →
BRCA	OS	Median	All	0.181	0.579	.029	4	view →
LGG	OS	Median	All	0.307	0.799	.012	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MUC13–HNSC (DFS)

Open the HNSC breakdown →